Literature DB >> 8124668

Stimulation of type IV collagenase expression by linoleic acid in a metastatic human breast cancer cell line.

X H Liu1, D P Rose.   

Abstract

Linoleic acid (LA), an omega-6 fatty acid, enhanced the appearance of type IV collagenase activity in culture medium conditioned by the metastatic MDA-MB-435 human breast cancer cell line; this effect was maximal with 0.75 microgram/ml LA. Zymography showed an increase in the gelatinolytic 92 kDa metalloproteinase, a form associated with the metastatic phenotype, during culture in the presence of 0.75 microgram/ml LA. Indomethacin, 20 micrograms/ml, completely suppressed the stimulation of collagenase by LA, suggesting a role for the eicosanoids. The tumor cells expressed mRNA for both the 72 and 92 kDa isoforms of type IV collagenase. Basal levels of the 92 kDa mRNA were much higher; both were up-regulated by LA despite the absence of detectable 72 kDa activity in conditioned medium.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8124668     DOI: 10.1016/0304-3835(94)90136-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line.

Authors:  Ellen Ackerstaff; Barjor Gimi; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

2.  Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells.

Authors:  Linda T Senbanjo; Hanan AlJohani; Mohammed AlQranei; Sunipa Majumdar; Tao Ma; Meenakshi A Chellaiah
Journal:  Cancer Drug Resist       Date:  2020-08-21

3.  Eicosanoids as mediators of linoleic acid-stimulated invasion and type IV collagenase production by a metastatic human breast cancer cell line.

Authors:  X H Liu; J M Connolly; D P Rose
Journal:  Clin Exp Metastasis       Date:  1996-03       Impact factor: 5.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.